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Simple Summary: The risk of prostate cancer development, the second most commonly occurring
cancer in men overall, increases strongly with age. About 10% of patients, however, are diagnosed
with early-onset prostate cancer (age at diagnosis: ≤55 years). This is considered to be a distinct
clinical and pathological phenotype with a poor prognosis. Generally, prostate cancer cells express
high quantities of prostate-specific membrane antigen (PSMA) on their surface. Radioligand therapy
is a type of treatment, which, among other available agents, uses the beta-emitting radionuclide
177Lutetium (177Lu) and a PSMA-targeting ligand termed PSMA-617 for internal irradiation of
metastatic prostate cancer cells. The aim of our retrospective study was to assess the efficacy and
safety of radioligand therapy with 177Lu-PSMA-617 in early-onset metastasized castration-resistant
prostate cancer patients refractory to chemotherapy. Special emphasis was placed on the patients’
response to the treatment and survival. The study provides support for the expected shorter survival
compared to heterogenous patient groups.
Abstract: The aim of this retrospective study was to assess the outcome of patients with metastasized
castration-resistant early-onset prostate cancer refractory to chemotherapy receiving radioligand
therapy with 177Lutetium-PSMA-617 (LuPSMA-RLT). Twenty-five patients of ≤55 years of age at
prostate cancer diagnosis, treated with a median of four (IQR 2–6) cycles (mean of 7.7 ± 1.4 GBq per
cycle) every 6–8 weeks, were analyzed. Survival outcome was calculated based on the Kaplan–Meier
method. The median progression-free survival (PFS) was 3.8 months (95% CI 2.3–5.3), and overall
survival (OS) was 8.5 months (95% CI 6.2–10.8). An initial PSA reduction (≥ 50%) was observed
in 9/25 (36%) of patients without being significantly associated with OS (p = 0.601). PSA response
(PSA decline ≥50% at 12 weeks) was observed in 12/25 (48%) of patients and significantly associated
with longer OS (16.0 months, 95% CI 7.4–24.6 vs. 4.0 months, 95% CI 1.1–6.9, p = 0.002). Imaging-
based response using 68Ga-PSMA-11-PET/CT after two to three cycles was seen in 11/25 (44%).
Additionally, responders had a significantly longer median PFS (8.7 months, 95% CI 1.3–16.1 vs.
1.9 months, 95% CI 1.7–2.2, p < 0.001) and OS (16.0 months, 95% CI 7.6–24.4 vs. 4.0 months, 95% CI
0.9–7.1; p = 0.002). Intra- or post-therapeutic toxicity was graded according to the CTCAE v5.0 criteria.
Newly developing grade ≥ 3 anemia, leukopenia, and thrombocytopenia occurred in three (12%),
one (4%), and three (12%) patients, respectively. One patient showed renal toxicity (grade ≥ 3) during
follow-up. Pain palliation (>2 level VAS decline) was achieved in 9/14 (64%) and performance status
improvement (ECOG level decline ≥ 1) in 8/17 (47%) of patients. Compared to previous reports,
radioligand therapy with 177Lu-PSMA-617 in metastasized castration-resistant early-onset prostate
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cancer patients refractory to chemotherapy yields similar response rates with a comparable safety
profile, but is associated with shorter survival.
Keywords: PSMA; 177Lu-PSMA-617; early-onset prostate cancer; metastatic castration-resistant
prostate cancer; younger
1. Introduction
Prostate cancer is considered a disease of advanced age [1]. Nevertheless, about 10%
of patients are initially diagnosed under the age of 55 years [2]. The increasing incidence of
prostate cancer, especially in this age group, which may be attributed in part to the more
prevalent use of prostate-specific antigen (PSA) testing [3], has led to defining this distinct
phenotype with higher cancer-specific mortality as early-onset prostate cancer (HR 1.22
[95% CI 1.10–1.49] compared to patients aged 60–69 years) [2]. Early-onset prostate cancer
is known to harbor an aggressive disease course yielding an elevated risk of disease pro-
gression and developing metastatic disease [2,4,5]. A large metanalysis on 318,774 prostate
cancer patients showed a comparatively lower rate of organ-confined disease in younger
patients (compared to an age > 55 years at diagnosis and older, p < 0.001) [6]. A large
study of 3,006 prostate cancer patients with stage IV disease revealed that metastatic early-
onset prostate cancer may also be less responsive to androgen deprivation therapy (ADT)
compared to middle-aged (≥56 and ≤65 years) and elderly (≥66 years) patients. Overall
survival (OS) at 5 years was significantly worse in the early-onset patient group than that
in the middle-aged or elderly group (36.3%, 95% CI 25.1–49.3; 62.1%, 95% CI 57.4–66.6;
and 59.8%, 95% CI 57.1–62.5; respectively) [7]. Cancer-specific survival and progression-
free survival (PFS) in the early-onset prostate cancer group were also significantly worse
compared to the middle-aged and elderly groups (p < 0.001 and p = 0.002, respectively) [7].
For patients with metastatic prostate cancer failing castration with ADT, only few
palliative systemic treatments exist. Taxane-based chemotherapy (i.e., docetaxel and cabaz-
itaxel), new generation antihormonal therapy (i.e., abiraterone acetate and enzalutamide),
and, in the presence of symptomatic bone dominant disease, 223Radium dichloride con-
stitute the standard treatment options in all age groups [8–13]. Previous studies reported
a generally less favorable outcome for patients with early-onset prostate cancer (EOPC)
at the metastatic castration-resistant stage but a similar response to chemotherapeutic
agents [14,15]. The overexpression of prostate-specific membrane antigen (PSMA) in
prostate cancer cells is the rationale for radioligand therapy using small-molecule in-
hibitors with high affinity to PSMA, such as PSMA-617, commonly labelled with beta-
emitting 177Lutetium (LuPSMA-RLT). Several studies, including the recently published
phase III VISION trial, revealed the safety and efficacy of LuPSMA-RLT in metastatic
castration-resistant prostate cancer patients after failing at least one line of taxane-based
chemotherapy [16]. To date, however, no dedicated analysis of LuPSMA-RLT in metasta-
sized castration-resistant EOPC patients is available.
This study aimed to investigate the safety and efficacy of LuPSMA-RLT in chemo-
refractory patients with metastasized castration-resistant EOPC. The impact of response to
treatment on survival outcome was of special interest.
2. Materials and Methods
2.1. Patients
We retrospectively analyzed 25 patients with metastasized castration-resistant EOPC
who were treated with 177Lu-PSMA-617 in our institution and were followed-up for a mini-
mum of 6 months. All patients received at least one line of taxane-based chemotherapy prior
to LuPSMA-RLT, which was performed if all remaining standard treatment options failed or
were not applicable. Baseline characteristics are outlined in Table 1. Further eligibility crite-
ria for LuPSMA-RLT included sufficient PSMA-expression in pretherapeutic 68Ga-PSMA-11
Cancers 2021, 13, 4193 3 of 11
PET/CT scan, estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73 m2, white
blood cells ≥ 2.00 × 109/L, platelets ≥ 75 × 109/L, and hemoglobin (Hb) ≥ 8.0 g/dL.
Three patients with isolated grade III anemia (7.6, 7.7, and 7.7 g/dL) at baseline and
no other treatment alternatives were treated. Next generation sequencing (NGS) was
performed in 6/25 patients. Three patients comprised a BRCA2 point mutation, and
one patient showed a BRCA1 point mutation. Two patients were carriers of an FGFR4
polymorphism and another two harbored a TP53 point mutation.
Table 1. Baseline characteristics.
Variable All Patients (n = 25)
Age at diagnosis, years 54 (51–55)
Age at LuPSMA-RLT initiation, years 62 (57–71)
Time to CR, years 4.5 (1.3–13.8)




PSA at LuPSMA-RLT initiation (ng/mL) 179 (69.5–1142)
PSA Doubling Time, months 2 (1.2–3.4)
Hemoglobin (g/dL) 11 (9.5–11.9)
White blood cells (109/L) 6.2 (5.1–7.2)
Platelets (109/L) 276 (217–335)
eGFR (mL/min/1.73 m2) 95.3 (72.5–103.8)
Alkaline phosphatase (U/L) 235 (124–568.5)
Lactate dehydrogenase (U/L) 315 (268–509.5)
Disease involvement:
Bone metastases 24 (96)
Lymph node metastases 20 (80)













223Radium dichloride 5 (20)
Docetaxel 25 (100)
Cabazitaxel 15 (60)
Nontaxane chemotherapy ** 4 (16)
Data presented as median with interquartile range (IQR), or n (%), LuPSMA RLT: 177Lutetium-PSMA-617 radi-
oligand therapy, CR: castration resistance, PSA: prostate-specific antigen, eGFR: estimated glomerular filtration
rate, VAS: Visual Analogue Score, ECOG: Eastern Cooperative Oncology Group, *: for available patients (n = 21),
** including one or more regimens: cisplatin, etoposide, 5-FU, carboplatin AUC 5, oxaliplatin, capecitabine,
mitoxantrone.
The initiation of treatment was decided by a multidisciplinary tumor board of experts.
All patients signed a written informed consent and agreed to the scientific analysis of their
data. The retrospective analysis was approved of by a local committee on ethics.
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2.2. 177Lutetium-PSMA-617 Radioligand Therapy
LuPSMA-RLT was performed every 6–8 weeks with a standard activity of 7.4 GBq and
was modified when necessary. The PSMA-617 ligand was provided by ABX (Advanced
Biochemical Compounds GmbH, Radeberg, Germany) and labelled in-house with 177LuCl3
(ITM Isotopen Technologien München AG, Garching/Munich, Germany) as described in
detail previously [17,18]. In order to limit xerostomia, salivary glands were cooled with
ice packages for 2 h beginning 30 min before the administration. 177Lu-PSMA-617 was
administered intravenously in 30–60 s preceded and followed by 1000 mL 0.9% NaCl
solution infusion. The distribution of the radionuclide was recorded using planar whole-
body scintigraphy at 24 h and 48 h p.i. All treatment cycles were carried out as in-patient
procedures at the nuclear medicine therapy ward.
2.3. Response Assessment
PSMA-based imaging response was performed every 2–3 cycles using the recent con-
sensus on 68Ga-PSMA-11 PET/CT imaging response assessment [19]: partial response (PR,
reduction of uptake and tumor PET volume by >30%), stable disease (SD, uptake and tumor
PET volume ± ≤30%; no new lesions), and progression (PD, appearance of >2 new lesions
or uptake or tumor PET volume ≥30% increased). Prostate-specific antigen (PSA) changes
were classified as: response (≥50% decline 12 weeks after treatment initiation), progression
(≥25% increase exceeding 2 ng/mL, confirmed by a second measurement ≥ 3 weeks apart,
according to the PCWG3 criteria [20]), and stable (values between <50% decline and <25%
increase). Initial PSA change after one cycle was not considered for response assessment if it
was not accompanied by other confirming evidence. The visual analog scale (VAS; ranging
from 0 to 10) and Eastern Cooperative Oncology Group (ECOG) scale were assessed at
baseline and at each treatment cycle and used to evaluate the pain and performance status.
2.4. Toxicity Assessment
Hematological (hemoglobin (Hb), white blood cells (WBC), platelets (PLT)) and renal
(eGFR) toxicity evaluation was performed through a blood workup routine at baseline, prior
to each therapy cycle, 2–4 weeks after each cycle and in 6–12 week intervals throughout
follow-up. The severity of adverse events was graded based on the Common Terminology
Criteria for Adverse Events (CTCAE), version 5.0, with grade ≥ 3 toxicities deemed
significant. Mouth dryness was evaluated at every LuPSMA-RLT cycle using a modified,
patient self-reported eight-item xerostomia questionnaire [21].
2.5. Data Analysis
Statistical analyses were performed using SPSS software (IBM SPSS Statistics 27.0,
Armonk, NY, USA). The significance level was set two-sided at p < 0.05. The presenta-
tion of the results was conducted either as a median with interquartile range (IQR) or
mean ± standard deviation for continuous variables, and categorical variables were pre-
sented as frequencies with respective percentages. The Paired-Samples T Test was used to
compare intraindividual changes in continuous biochemical parameters. Imaging-based
PFS was defined as the time interval from LuPSMA-RLT initiation to the date of the first
progression, or death, if no imaging-based progression occurred (defined according to
the PCWG3 criteria) [20]. Overall survival (OS) was defined as the time from treatment
initiation to death from any cause; censoring was carried out if the patient was alive at
the time of analysis. PFS and OS were calculated based on the Kaplan–Meier method
(log-rank testing).
3. Results
Twenty-five patients with metastasized castration-resistant EOPC were treated with
LuPSMA-RLT for a median of four (IQR 2–6) cycles and 7.7 ± 1.4 GBq per cycle reaching a
cumulative activity of 31.3 ± 21.3 GBq.
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3.1. Response
PSA decline (≥50%) after 12 weeks occurred in 12/25 (48%) patients; 6/25 (24%)
remained stable. Seven (28%) patients showed PSA progression (n = 4) or died (n = 3)
within 12 weeks. Imaging assessment showed PR in 11/25 (44%) patients, and 4 patients
(16%) had SD. Ten (40%) patients had PD (n = 7) or were deceased before the assessment
(n = 3). An example of a disease course on 68Ga-PSMA-11 PET/CT imaging is provided in
Figure 1.
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Mean follow-up was 8.7 ± 6.1 months. Twenty-one (84%) patients died by the time of 
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Objective imaging response was associated with a significantly longer median OS (PR:
16.0 months, 95% CI 7.6–24.4 vs. SD/ PD or deceased: 4.0 months, 95% CI 0.9–7.1, p = 0.002;
Figure 3a). Three patients died before the first PSMA-based imaging response assessment.
The median overall survival of the remaining 22 patients was: PR (16.0 months, 95% CI
7.6–24.4, p = 0.002), SD (8.5 months, 95% CI 7.2–9.8), and PD or deceased (3.0 months,
95% CI 1.5–4.6; Figure 3b). In patients achieving disease control (PR and SD, n = 15), the
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median PFS was 5.6 months (95% CI 4.5–6.8), and the median OS of 13.0 months (95% CI
5.0–21.0) was significantly longer compared to non-responders (3.0 months, 95% CI 1.5–4.6,
p = 0.001).
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Figure 4. Kaplan– eier survival curves. (a) PSA decline (≥50%) after the first cycle and respective
S in months; (b) PSA decline (≥50%) 12 weeks after LuPSMA-RLT nitiatio and r spective OS
in months.
3.3. Safety
t baseline, 23 (92 ) patie ts a a e ia (16 ra e , ra e 2, 3 ra e 3), 1 ti t
had (4 ) leukopenia (1 grade 1), 5 tie ts a ( ) t r cytopenia (4 ra e 1,
grade 2), and 4 patients had (16%) renal function grade 2. Hb, WBCs, and PLTs showed
a minor yet significant absolute decline through the course of LuPSMA-RLT. ean
changed from 10.7 ± 1.8 to 10.2 ± 1.9 g/dL (p < 0.001), WBCs from 6.4 ± 1.8 × 109/L
to 5.0 ± 1.7 × 109/L (p < 0.001), and PLTs from 262 ± 92 × 109/L to 182 ± 88 × 109/L
(p = 0.008).
Newly developing grade ≥ 3 hematological toxicity after at least one cycle of LuPSMA-
RLT or during follow-up was observed: significant anemia (grade ≥ 3) in three (12%)
patients, leukopenia in one patient (4%), and thrombocytopenia (grade ≥ 3) in three patients
(12%). During the follow-up period, grade ≥ 3 anemia, leukopenia, and thrombocytopenia
were reversible in 1/5 (20%) patients, 1/1 (100%), and 1/3 (33%), respectively.
Nephrotoxicity (grade ≥ 3) occurred in one (4%) patient, which was reversible during
follow-up. We found no significant xerostomia during LuPSMA-RLT and the follow-up
period; however, grade 1 or 2 xerostomia began in six (24%) of the patients after a median
of two (IQR 1–4) cycles. A summary of the adverse events is shown in Table 2.
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Table 2. Hematologic, renal, and salivary gland toxicity grades based on CTCAE v5.0. at baseline
and after at least one cycle of LuPSMA-RLT or during follow-up.
Toxicity
Baseline, n (%) Post-Therapeutic, n (%)
Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4
Anemia 20 (80) 3 (12) 20 (80) 5 (20)
Leukopenia 1 (4) 0 (0) 12 (48) 1 (4)
Thrombocytopenia 5 (20) 0 (0) 7 (28) 3 (12)
eGFR * 4 (16) 0 (0) 7 (28) 1 (4)
Xerostomia 0 (0) 0 (0) 6 (24) 0 (0)
* Estimated glomerular filtration rate.
4. Discussion
This retrospective study is the first report addressing the outcome of patients with
metastatic castration-resistant early-onset prostate cancer treated with LuPSMA-RLT. The
observed biochemical response rate of 48% (12/25) at 12 weeks is similar to the findings of
previous studies on patients with different ages at diagnosis, and responders identified by
PSMA-based imaging benefitted from a significantly longer overall survival with a median
of 16.0 months (p = 0.002) [16,22,23]. Disease control was achieved in 60% (15/25), but the
median progression free survival of 5.6 months was relatively short [16,22,23].
In the most recent phase III VISION trial, Sartor et al. showed an imaging PR response
rate of 40% using RECIST criteria and bone scan [16]. Using the same criteria, Hofman et al.
reported an objective response rate of 49% in the phase II TheraP trial [22]. Concordantly,
44% (11/25) of the patients in our study showed a PR in PSMA-based imaging. Our
biochemical response rate (PSA-decline ≥ 50% at 12 weeks) was also comparable to the
findings of the VISION trial (48% vs. 46%) [16]. The prognostic relevance of initial PSA-
decline of ≥50% at 4 weeks after the first cycle of LuPSMA-RLT is unclear [24,25]. In our
study, 9/25 (36%) patients with an initial PSA decline ≥ 50% tended to live longer, but
the difference was not statistically significant (8.5 vs. 5.5 months, p = 0.601). Similarly, in
the WARMTH multicenter study by Ahmadzadehfar et al., PSA response to the first cycle
measured after 8 weeks had no significant impact on overall survival (PSA response ≥ 50%:
41.5%, p = 0.6) [23].
The response to LuPSMA-RLT seems to be independent of age at diagnosis, yielding
similar imaging and biochemical response rates in patients with metastasized castration-
resistant EOPC and other age groups. However, the median PFS of 3.8 months (95%
CI 2.3–5.3) in our study group is comparatively short, indicating an earlier progression
in patients with metastasized castration-resistant EOPC. The VISION trial reported an
imaging PFS of 8.7 months for the patients in the 177Lu-PSMA-617 plus Standard Care
arm, and the TheraP trial showed a PFS of 5.1 months in the experimental group receiving
177Lu-PSMA-617 [16,22]. This difference in PFS may have been partly caused by the
higher diagnostic ability of 68Ga-PSMA-11 PET/CT imaging used for treatment assessment
in our study as compared to computer tomography plus bone scan [26]. On the other
hand, a study by Barber et al. investigating the influence of previous chemotherapy
on the outcome of patients receiving LuPSMA-RLT using 68Ga-PSMA-11 PET/CT for
response assessment showed a longer median PFS in both groups compared to our study
on metastasized castration-resistant EOPC [27]. The median PFS in chemo-refractory
patients was 6.0 months (vs. 8.8 months in chemo-naïve) with a mean age of 69 years at
treatment initiation. Furthermore, few reports suggest an association between younger
age at initiation of LuPSMA-RLT and poor outcome. Heck et al. studied 100 patients
with a median age of 72 years (IQR 66–76) and found a significant decrease in the risk
of progression (HR 0.7, 95% CI 0.5–0.9, p = 0.01) and death of any cause (HR 0.7, 95% CI
0.5–1.0, p = 0.07) with every 10-year increase in age [28]. This may be the result of more
metastasized castration-resistant EOPC among patients with younger age at the time of
treatment initiation.
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In our study investigating patients younger than 55 years old at diagnosis, the median
age at treatment initiation was 62 (IQR 57–71). Metastasized castration-resistant EOPC
patients with disease control by PSMA-based imaging during the course of treatment lived
significantly longer than non-responders (13.0 months, 95% CI 5.0–21.0 vs. 3.0 months, 95%
CI 1.5–4.6; p = 0.001). However, the median OS of 8.5 months in the whole study group
was shorter comparing to the reported median OS in the prospective trials with signifi-
cantly higher ages at treatment initiation, such as in the VISION trial (OS, 15.3 months;
age, 70 years), LuPSMA trial (OS, 13.5 months; age, 71 years), and RESIST-PC trial (OS,
14 months; age, 74 years), although the age at diagnosis was not presented [16,29,30]. Simi-
lar median ages at the treatment initiation, ranging from 70 to 75 years, were also reported
by the majority of the previous retrospective studies on patients treated with LuPSMA-
RLT [31–35]. Although the ages at diagnosis were not explicitly displayed, the significantly
older cohorts at LuPSMA-RLT initiation imply the inclusion of a relatively small proportion
of metastasized castration-resistant EOPC patients with a reportedly distinguished, more
aggressive course of disease resulting in shortened sojourn times [2,4,36].
A stronger genetic component with a characteristically higher incidence of germline
alterations such as TMPRSS2–ERG fusions and BRCA1/2 mutations has been considered
responsible for the poor differentiation and higher mortality [37–42]. A study on 333 con-
secutive castration-resistant prostate cancer patients revealed an OS of 5.5 years (95%
CI 3.0–7.5) in CR-EOPC patients compared to 6.7 years (95% CI 5.9–8.4) in those aged
55–64 years, and 7.8 years (95% CI 6.6–9.3) in the age group of 65–74 years at prostate
cancer diagnosis, respectively [15]. In six patients with NGS analysis in our study, four
patients were carriers of BRCA1 (n = 1) / BRCA2 (n = 3), TP53 (n = 2) point mutations,
and FGFR4 (n = 2) polymorphism. BRCA2 mutations may also lead to more rapid taxane
resistance in metastasized castration-resistant prostate cancer patients [43]. A large study
on 2019 patients with prostate cancer showed that BRCA1/2 status is an independent
prognostic value for OS (HR 1.9; 95% CI 1.1–3.3; p = 0.012) [44].
The rate of significant toxicity in our study is comparable to that of previous studies
on heterogenous patients. Hematotoxicity was the most frequent adverse event with newly
appearing grade 3 anemia during LuPSMA-RLT or during follow-up in three (12%) patients,
grade 3 leukopenia in one (4%) patient, and grade 3 thrombocytopenia in three (12%)
patients. These findings are in concordance to the VISION trial with grade ≥ 3 anemia
occurring in 12.9%, grade ≥ 3 leukopenia in 2.5%, and grade ≥ 3 thrombocytopenia in
7.9% [16]. In the phase II LuPSMA trial by Hofman et al., grade ≥ 3 anemia occurred in
13%, grade ≥ 3 leukopenia in 1%, and grade ≥ 3 thrombocytopenia in 13% [29]. In our
study, one patient with a renal impairment at baseline (grade 2) experienced a reduction
to grade 3 due to a complicated suprapubic urinary catheter and coagulum formation
in the urinary bladder. Renal function returned to the baseline level after appropriate
anti-inflammatory treatment. In line with previous studies reporting the renal safety of
RLT with LuPSMA-RLT, no significant treatment-induced nephrotoxicity was observed in
our patient group [45,46].
The main limitations of our study are the small sample size and its retrospective
nature, which inevitably weaken the comparability with the prospective trials and the
conclusions drawn. The short survival of the patients limited the follow-up period in our
study, preventing the assessment of long-term renal safety. To improve the outcome of RLT,
combination therapy by adding antiandrogen therapies or chemotherapeutic agents to
LuPSMA-RLT, or by using the tandem approach with 225Actinum-PSMA-617/177Lutetium-
PSMA-617, may be worth considering. Moreover, genetic sequencing was only performed
in a minority of patients. Considering the strong genetic component in patients with
early-onset prostate cancer, future studies focusing on genetic profiling may provide useful
information that can help personalize LuPSMA-RLT.
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5. Conclusions
The response to radioligand therapy with 177Lu-PSMA-617 seems to be independent
of the presence of early-onset prostate cancer (EOPC); however, the less favorable survival
outcome observed in our study may indicate a more aggressive disease course. Expectedly,
the safety of LuPSMA-RLT does not seem to be compromised in metastasized castration-
resistant EOPC patients. Comparative studies on age at diagnosis of prostate cancer and
the patients’ outcome after LuPSMA-RLT are needed.
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